Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JESSICA BAUMAN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1619139235
CMS profile
579955
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,520.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $2,520.00 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $2,520.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JESSICA BAUMAN

NPI 1619139235 · CMS profile ID 579955

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619139235?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619139235?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619139235?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1619139235?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $2,520.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $2,520.0006/10/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949352739 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,346.90 6
PY2021 $6,402.50 6
PY2022 $2,520.00 1
PY2023 $13,235.53 5
PY2024 $3,945.00 3
PY2025 $4,182.50 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $662,530.20 43
PY2024 Recipient $4,600.00 2
PY2024 Principal investigator $597,434.60 56
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $615,260.38 77
PY2022 Principal investigator $513,473.56 47
PY2021 Principal investigator $536,056.62 88
PY2020 Recipient $3,200.00 1
PY2020 Principal investigator $550,482.65 74
PY2019 Principal investigator $501,598.41 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $5,947.14 12/31/2024 Covered Recipient Teaching Hospital
American Oncologic Hospial
Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma R,M cSCC No dispute reported 06/30/2026 1136413241
Principal investigator 1 Merck Sharp & Dohme LLC $9,076.99 12/31/2024 Covered Recipient Teaching Hospital
American Oncologic Hospial
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1136413754
Principal investigator 1 Merck Sharp & Dohme LLC $177,843.96 12/31/2024 Non-covered Recipient Entity
Fox Chase Cancer Center-Hematology,Oncology
A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation MK-7684A Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer KEYVIBE-003 No dispute reported 06/30/2026 1136429607
Principal investigator 1 Merck Sharp & Dohme LLC $37,179.70 12/31/2024 Covered Recipient Teaching Hospital
American Oncologic Hospial
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 1136431102
Principal investigator 1 Incyte Corporation $1,500.00 12/26/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695489
Principal investigator 1 Aveo Pharmaceuticals, Inc. $6,240.66 12/16/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
TBD - WCT/AVEO No dispute reported 06/30/2026 1143504330
Principal investigator 1 Aveo Pharmaceuticals, Inc. $21,956.46 12/09/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
Not supplied No dispute reported 06/30/2026 1143504311
Principal investigator 1 Aveo Pharmaceuticals, Inc. $32.75 12/09/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
Not supplied No dispute reported 06/30/2026 1143504324
Principal investigator 1 Aveo Pharmaceuticals, Inc. $405.60 12/03/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
Not supplied No dispute reported 06/30/2026 1143504302
Principal investigator 1 Genmab U.S., Inc. $506.52 11/27/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1125189138
Principal investigator 1 Incyte Corporation $2,014.60 11/27/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695481
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 11/19/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
TBD - WCT/AVEO No dispute reported 06/30/2026 1143504336
Principal investigator 1 Aveo Pharmaceuticals, Inc. $9,123.39 11/06/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
Not supplied No dispute reported 06/30/2026 1143504351
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,300.00 10/21/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
TBD - WCT/AVEO No dispute reported 06/30/2026 1143504307
Principal investigator 1 Aveo Pharmaceuticals, Inc. $25,040.18 10/07/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
Not supplied No dispute reported 06/30/2026 1143504316
Principal investigator 1 Aveo Pharmaceuticals, Inc. $20,780.66 10/07/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
Not supplied No dispute reported 06/30/2026 1143504346
Principal investigator 1 Incyte Corporation $4,464.90 10/04/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695477
Principal investigator 1 Incyte Corporation $13,666.50 10/04/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695479
Principal investigator 1 Genmab U.S., Inc. $8,825.00 09/19/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1125189131
Principal investigator 1 Genmab U.S., Inc. $3,932.73 09/19/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1125189135
Principal investigator 1 Amgen Inc. $17.33 09/18/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
AMG 510 Expanded access ex EU w/LTFU No dispute reported 06/30/2026 1096308207
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,500.00 09/16/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
TBD - WCT/AVEO No dispute reported 06/30/2026 1143504274
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13,415.54 09/11/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
TBD - WCT/AVEO No dispute reported 06/30/2026 1143504284
Principal investigator 1 Incyte Corporation $20.26 08/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695487
Principal investigator 1 Aveo Pharmaceuticals, Inc. $9,209.23 08/05/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
Not supplied No dispute reported 06/30/2026 1143504279
Principal investigator 1 Aveo Pharmaceuticals, Inc. $35,886.93 08/05/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
Not supplied No dispute reported 06/30/2026 1143504294
Principal investigator 1 Merck Sharp & Dohme LLC $3,050.00 07/15/2024 Covered Recipient Teaching Hospital
American Oncologic Hospial
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1136413675
Principal investigator 1 Aveo Pharmaceuticals, Inc. $20,061.80 07/08/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
TBD - WCT/AVEO No dispute reported 06/30/2026 1143504288
Principal investigator 1 Genmab U.S., Inc. $4,932.50 06/26/2024 Non-covered Recipient Entity
THE INSTITUTE FOR CANCER RESEARCH
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1125193384
Principal investigator 1 Genmab U.S., Inc. $1,500.00 06/26/2024 Non-covered Recipient Entity
THE INSTITUTE FOR CANCER RESEARCH
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1125193388
Recipient PFIZER INC. $1,400.00 06/26/2024 Covered Recipient Physician LORLATINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130904209
Principal investigator 1 Genmab U.S., Inc. $1,000.00 05/02/2024 Non-covered Recipient Entity
THE INSTITUTE FOR CANCER RESEARCH
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1125193392
Principal investigator 1 Genmab U.S., Inc. $8,241.00 05/02/2024 Non-covered Recipient Entity
THE INSTITUTE FOR CANCER RESEARCH
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1125193396
Principal investigator 1 Genmab U.S., Inc. $10,679.53 05/02/2024 Non-covered Recipient Entity
THE INSTITUTE FOR CANCER RESEARCH
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1125193400
Principal investigator 1 Genmab U.S., Inc. $8,241.00 04/25/2024 Non-covered Recipient Entity
THE INSTITUTE FOR CANCER RESEARCH
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1125193380
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,000.00 04/12/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
Not supplied No dispute reported 06/30/2026 1160985005
Principal investigator 1 Merck Sharp & Dohme LLC $6,230.84 03/22/2024 Covered Recipient Teaching Hospital
American Oncologic Hospial
Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma R,M cSCC No dispute reported 06/30/2026 1136412944
Principal investigator 1 Incyte Corporation $1,500.00 03/21/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695455
Principal investigator 1 Aveo Pharmaceuticals, Inc. $49,175.00 03/19/2024 Non-covered Recipient Entity
Fox Chase Cancer Center
Not supplied No dispute reported 06/30/2026 1160984781
Principal investigator 1 AstraZeneca Pharmaceuticals LP $57,318.25 03/13/2024 Non-covered Recipient Entity
THE INSTITUTE FOR CANCER RESEARCH
A Phase 3 Randomized Double-blind Multicenter Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1110841236
Recipient PFIZER INC. $3,200.00 03/12/2024 Covered Recipient Physician ENCORAFENIB DACOMITINIB BINIMETINIB MULTI PRODUCT LORLATINIB CRIZOTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1131068896
Principal investigator 1 Incyte Corporation $72.45 03/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695461
Principal investigator 1 Incyte Corporation $99.85 03/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695467
Principal investigator 1 Incyte Corporation $51.05 03/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695483
Principal investigator 1 Incyte Corporation $10.21 02/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695457
Principal investigator 1 Incyte Corporation $66.44 02/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695459
Principal investigator 1 Incyte Corporation $14.49 02/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695463
Principal investigator 1 Incyte Corporation $12.51 02/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695465
Principal investigator 1 Incyte Corporation $19.97 02/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695469
Principal investigator 1 Incyte Corporation $25.02 02/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695471
Principal investigator 1 Incyte Corporation $21.44 02/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695473
Principal investigator 1 Incyte Corporation $12.51 02/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695475
Principal investigator 1 Incyte Corporation $10.21 02/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695485
Principal investigator 1 Incyte Corporation $12.51 02/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695491
Principal investigator 1 Incyte Corporation $12.51 02/08/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695493
Principal investigator 1 GlaxoSmithKline, LLC. $603.67 01/31/2024 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 1127540811
Principal investigator 1 GlaxoSmithKline, LLC. $10,572.81 01/31/2024 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 1127540813
Principal investigator 1 Incyte Corporation $1,000.00 01/18/2024 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1134695453